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Significant sac retraction after endovascular
aneurysm repair is a robust indicator of durable
treatment success
Rabih Houbballah, MD, Marek Majewski, MD, and Jean-Pierre Becquemin, MD Creteil, France
Objectives: The principal aim of this study was to demonstrate that significant sac retraction (SSR) was a predictive marker
of durable success after endovascular aortic repair (EVAR). If verified, follow-up (FU) of patients with SSR may become
unnecessary. In addition, the clinical features of the patients and aneurysms were analyzed to identify predictive factors
of SSR.
Methods: A group of 371 patients treated by EVAR had a complete clinical exam, computed tomography (CT) scan, and
duplex scan follow-up. Data were collected prospectively and analyzed retrospectively. We assessed the difference between
the largest diameter of the aneurysm (D) and the diameter of the stent-graft body (D1) on each postoperative CT scan.
SSR was defined as a minimum of 75% reduction of this difference between the first and any of the following CT scans.
Treatment success was defined as survival free of aneurysm-related death, type I or III endoleak, aneurysm expansion
exceeding 5 mm, rupture, surgical conversion, migration, and graft occlusion. To assess the predictive factors of SSR, we
performed a multivariable analysis and a logistic regression of the most significant variables.
Results: SSR was observed in 24.8% (92/371) of the patients after an average of 26  21 months of FU. The mean
duration of FU in this group was 50  26 months (vs 45  25 months; P NS). Survival was significantly longer in the
SSR group (96  3 months vs 93  3 months; P < .05). No rupture, surgical, or endovascular conversion was reported
in the SSR group. The frequency of type I (2.2% vs 15.4%; P < .001), type II (3.3% vs 29.4%; P < 10-6), and secondary
interventions (3.3% vs 13.3%;P < .05) was lower in the SSR group. All type I and III endoleaks were diagnosed and
treated before SSR detection. Since SSRwas detected, treatment success remained until last follow-up in 98.9% (91 of 92)
of the patients. The independent predictive factors of SSR were abdominal aortic aneurysm (AAA) diameter <55 mm
(odds ratio [OR] 3.91; 95% confidence interval [CI]: 2.16-7.11), infra renal aorta diameter<23 mm (OR 2.96; 95% CI:
1.74-5.03), and a proximal neck length >22 mm (OR 2.41; 95% CI: 1.42-4.10).
Conclusion: In this series, SSR was accurately predictive of a durable success after EVAR. It occurred mostly in patients
with a favorable anatomy. Less intensive follow-up work up seems to be safe in patients with SSR. (J Vasc Surg 2010;
52:878-83.)Since the first use of a stent-graft reported by Volodos,1
it is now established that endovascular aortic repair (EVAR)
is the less invasive alternative to conventional surgery for
the treatment of abdominal aortic aneurysm (AAA). The
results of the principal randomized trials2,3 and studies of
international registries4-6 have demonstrated the short-
term benefits of endovascular surgery over conventional
surgery: lower early postoperative mortality and morbidity
rates, less blood loss, shorter hospital and intensive care
stays, and a quicker return to active life. The mechanical
deterioration of stent grafts and endoleaks observed in
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878medium- and long-term studies7,8 has led to indefinite
periods of post-surgical monitoring for patients treated
with EVAR. Noll et al9 showed, that at 5 years, the radio-
logical follow-up by computed tomography (CT) scan of
patients without endoleak was responsible for an overall
cost increase of 32.5%. Therefore, it would be valuable to
identify factors reproducibly predictive of long-term clini-
cal success authorizing a simplification of the follow-up.
The concept of significant sac retraction (SSR) was first
described in 2000. Rhee et al defined SSR as an aneurysmal
sac diameter less than 3.5 cm after EVAR,10 whereas com-
plete resolution of the aneurysm was defined by the Amer-
ican consensus conference11 as a decrease by more than
90% of the extraluminal volume. So far, no study has
analyzed either the correlation between SSR and treatment
success or the persistence in time of an SSR. The aim of this
study was to investigate the correlation between SSR and
treatment success, the durability of treatment success in
SSR patients, and the predictive factors of SSR.
METHODS
Between January 1995 and December 2006, 371 pa-
tients were followed at Henri Mondor Hospital in Créteil
following non-emergency treatment for infra-renal AAA by
ersal
D1 
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thoracoabdominal aortic aneurysm, symptomatic or
ruptured aneurysm, infectious aneurysm, anastomotic
pseudoaneurysm, or isolated iliac aneurysm were not
included in this study. Clinical, demographic, and radio-
logical data were collected prospectively in a specific,
computerized database (Logit, Fontenay Sous Bois,
France). AAA treatment was considered when the max-
imal diameter was at least 50 mm and/or when an
increase in the maximal diameter of at least 5 mm was
observed over a period of 6 months. Endovascular treat-
ment was considered when the patient was not eligible
Fig 1. Definition of SSR. A, Sagittal view. B, Transv
Fig 2. SSR in a patient with a 55 cm AAA, at 2 year
diameter, D  55 mm. Stent graft diameter, D1  28 m
Aneurysm diameter, D  33 mm. Stent graft diameter.for open surgery regarding the French National Agencyof Health Accreditation and Evaluation criteria,12 or
when the patient expressed a desire to undergo stent
graft implantation, having displayed the anatomical re-
quirements listed in the American consensus document
published in 1997.13 Stent grafts were usually implanted
under general anaesthesia. Clinical and CT angiography
follow-up were scheduled at 1 month, 6 months, 12
months, and 18 months after EVAR, and annually there-
after. CT angiograms were interpreted by a vascular
surgeon and a vascular radiologist.
Judgment criteria. We studied the difference be-
tween the largest diameter of the aneurysm (D) and the
view. Preop, Preoperative; t, time point in follow-up.
ollow-up. A, Preoperative CT angiography. Aneurysm
, Postsurgical CT angiography at 2 years of follow-up.
28 mm.s of f
m. Bdiameter of the body of the stent graft (D1). SSR was
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time point t during follow-up (Figs 1 and 2).
DD1preop DD1t
DD1preop
 100 75
Until 2001, measurements were made manually from
CT angiograms using a pair of compasses. After 2001,
measurements were made on a Netvantage Windows Vol-
ume Show 3 platform (Infragistics, Elstree, United King-
dom) on the basis of a three-dimensional reconstruction.
We used the definition of treatment success proposed by
the American Vascular Surgery Society in 2002. Success
was defined as the absence of aneurysm-related mortality,
an absence of type I and III endoleaks, an absence of type II
endoleaks responsible for aneurysmal growth, an absence of
aneurysmal expansion by more than 5 mm or 20%, an
absence of rupture or surgical conversion, and an absence
of stent graft migration or failure.14 By extension, a treat-
ment failure was defined if any of the above listed compli-
cations was present. We searched for predictive factors of
SSR in preoperative data, focusing essentially on surgical
risk factors and AAA anatomy.We also compared outcomes
of patients with SSR according to our definition with
outcomes of patients with SSR according to previously used
definitions.10,11
Statistical analysis. Statistical analysis was carried out
with SAS version 9.1 (SAS Inc, Cary, NC), by the Clinical
Research Unit of the University of Créteil (Dr Patrick
Cunin). Quantitative data were expressed as means stan-
dard deviations, and qualitative data as a percentage. We
Table I. Demographic and clinical characteristics of the p
Total populatio
(n  371)
Age (years; mean  SD) 73  9
Diabetes 45 (12.1%)
Obesity (body mass index 30) 47 (12.7%)
Severe respiratory insufficiency 20 (5.4%)
Symptomatic carotid lesions 20 (5.4%)
End-stage renal failure 10 (2.7%)
Angor 82 (22.1%)
Major dyslipidemia 38 (10.2%)
Poorly-controlled arterial hypertension 5 (1.3%)
Active smoker 25 (6.7%)
SSR, Significant sac reduction.
Table II. Different type of endografts implanted
First generation endograft
● Vanguard (n  39; Boston Scientific, Natick, Mass),
● EVT (n  7; EndoVascular Technologies, Menlo Park, Calif)
● Stenford device (n  6; Stenford Groupe Valendons SA,
Nanterre, France)
● First-generation Gore device (n  3) (W.L. Gore & Associ-
ates, Flagstaff, Ariz)used 2 tests to compare qualitative variables and t tests tocompare quantitative variables. The level of significance was
fixed at P  .05. The threshold giving the best sensitivity/
specificity ratio for quantitative variables was identified by
plotting receiver operating characteristics (ROC) curves. A
multivariate analysis was carried out. As the variable ana-
lyzed was qualitative, logistic regression was carried out. A
stepwise descending procedure was used. Kaplan-Meier
survival analysis was used for follow-up study. Log rank
tests were used to compare the duration of follow-up
between several groups. Cox models were used for the
multivariate analysis of follow up duration.
RESULTS
Demographics. This population was at high cardio-
vascular risk (Table I), and 40% of the patients had associ-
ated cardiac, carotid, or lower limb vascular disease. Eight
different types of stent grafts were used. We classified the
stent grafts as “first-generation” or “second-generation”
(Table II). The mean duration of follow-up was 46  25
months (Table III). The size of the aneurysm remained
stable in 24.2% of the patients (90/371; change of less than
5 mm); it increased by more than 5 mm in 10.0% of the
patients (37/371) and decreased by at least 5 mm in 65.8%
of the patients (244/371). SSR was found in 24.8% of
patients (92/371).
The SSR event. The mean time to SSR detection was
23  3 months. The mean follow-up duration after the
detection of SSR was 26  21 months. No rupture, surgi-
cal, or endovascular conversion was reported in the SSR
group (Table III). All the type I and III endoleaks in the
ts
SSR group
(n  92)
Non-SSR group
(n  279) P value
71  8 74  9 .05
9 (9.8%) 36 (12.9%) .41
10 (10.9%) 37 (13.3%) .53
5 (5.4%) 15 (5.4%) .99
5 (5.4%) 15 (5.4%) .99
2 (2.2%) 8 (2.9%) .71
20 (21.7%) 62 (22.2%) .89
8 (8.7%) 30 (10.8%) .56
1 (1.1%) 4 (1.4%) .80
7 (7.6%) 18 (6.4%) .71
Second generation endograft
● Zenith (n  266; Cook, Bloomington, Ind),
● Excluder (n  27; W.L. Gore & Associates, Flagstaff, Ariz),
● AneuRx (n  16; Medtronic, Minneapolis, Minn)
● Talent (n  7; Medtronic, Minneapolis, Minn).atien
nSSR groupwere diagnosed and treated before the detection
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aneurysm. In that case, SSR was detected at 12months, but
the patient developed a persistent type II endoleak. At 24
months, his aneurysm sac re-expanded to 50 mm. He was
treated by inferior mesenteric and lumbar artery embolisa-
tion. At his last follow-up, the aneurysm size remained
stable. Except for one patient with a type I endoleak, all
complications in the TRS group (one type I endoleak, one
type III endoleak, and one persistent type II endoleak)
were diagnosed in patients initially treated with a first-
generation endograft. At the time of SSR diagnosis, mean
diameter of the aneurysm sac was 35 3mm, and themean
decrease in the difference between D and D1 was 82% 
8%. SSR was highly predictive of treatment success with a
specificity value and a positive predictive value of 98.9%.
Using the current definition, sensibility and negative pre-
dictive value of SSR were higher than using definitions
previously reported (Table IV).
Predictive factors of SSR. Three preoperative factors
were significantly different between SSR and non-SSR pa-
tients: the preoperative maximal anterior-posterior diame-
ter, the maximal diameter of the suprarenal, and the proxi-
Table III. Postsurgical follow-up
Total population
(n  371)
Mean follow-up  SD (months) 46  25
Death
N (%) 68 (18.3)
Rupture
N (%) 3 (0.8)
Surgical conversion
N (%) 13 (3.5)
Type I endoleak
N (%) 45 (12.1)
Type III endoleak
N (%) 6 (1.6)
Type II endoleak
N (%) 85 (22.9)
Persistent type II endoleak
N (%) 38 (10.5)
Secondary intervention
N (%) 43 (11.6)
Lost to follow-up
N (%) 49 (13.2)
SSR, Significant sac reduction.
Table IV. Correlation between SSR and clinical treatmen
literature definitions
SSR definition Incidence Sensibility Spe
75% 25% (92/371) 33%
90%a 4.8% (18/371) 6.5% 1
35 mmb 18% (67/371) 24% 1
aDecrease in this difference between the largest diameter of the aneurysm (D
point t during follow-up.
bAneurysm sac smaller than 3.5 cm.mal neck length (Table V). The thresholds were determinedand odds ratios (OR) were calculated. Three predictive fac-
tors of SSR were found: a preoperative external diameter
smaller or equal to 55 mm (OR 3.91 [95% confidence
interval (CI): 2.16-7.11]), a supra-renal aortic diameter
smaller or equal to 23mm (OR 2.96 [95%CI: 1.74-5.03]),
and a proximal neck length exceeding 22 mm (OR 2.41
[95% CI: 1.42-4.10]).
DISCUSSION
We found that SSR was an excellent indicator of treat-
ment success with a positive predictive value and a specific-
ity of 98.9%. The mean time between the detection of SSR
and the end of follow-up was 26 21 months. During this
period, only one patient displayed renewed growth of the
aneurysm. We can therefore assume, within the limitations
of our study, that the presence of SSR at 24 months of
follow-up is correlated with a high probability of long-term
treatment success.
Definition of SSR. Currently, two different defini-
tions of SSR are available in the literature. Based on volu-
metric assessment, SSR is assessed when the non-luminal
aneurysm volume (comprised between the stent graft and
SSR group
(n  92)
Non-SSR group
(n  279) P
50  26 45  25 NS
10 (10.9) 58 (20.8) .05
0 3 (1.1) NS
0 13 (4.7) .05
2 (2.2) 43 (15.4) .001
1 (1.1) 5 (1.8) NS
3 (3.3) 82 (29.4) .0001
1 (1.0) 39 (13.3) .001
3 (3.3) 40 (14.3) .05
2 (2.2) 47 (16.8) .001
cess; comparison between current definition and
ty Positive predictive value Negative predictive value
98.9% 34%
100% 27%
100% 31%
the diameter of the body of the stent graft (D1) greater than 90% at a timet suc
cifici
98.9%
00%
00%
) andthe inner aneurysm sac wall) is less than 10% of the original
JOURNAL OF VASCULAR SURGERY
October 2010882 Houbballah et alnon-luminal volume noted after endograft implanta-
tion.11,15 Volumetric measurements provide a reliable,
non-invasive method for studyingmorphological aneurysm
changes. This approach, however, is difficult to apply rou-
tinely as it requires a sophisticated, computerized technical
platform, highly complex algorithms, and is time consum-
ing (60 minutes).16 Conversely, aneurysm sac diameter
assessment is easy, reproducible, and reliable when studying
changes greater than 10% or 5 mm.11,17 Based on diameter
study, Rhee et al defined SSR as an aneurysmal sac with a
diameter smaller than 3.5 cm. This series included 70
patients followed up for 24 months. Overall, 44% of pa-
tients were lost to follow-up, and 16% had an SSR.10 In our
series, using the definition of Rhee et al or the American
consensus volumetric definition would have respectively
decreased the incidence of SSR to 18% (67/371) and 4.8%
(18/371). Our definition of SSR is based on a two-
dimensional study of the non-luminal space and evaluates
75% shrinkage, increasing consequently SSR incidence
without losing its high positive predictive value for treat-
ment success.
The limitations of SSR. To be useful, a predictive
factor must be reliable, reproducible, easy to interpret,
sensitive, and specific. The principal limitation of our
marker is its lack of sensitivity (33%). The fact that some
aneurysms do not retract despite the absence of detectable
complications18 may explain this lack of sensibility to detect
all treatment success. However, our definition of SSR ap-
pears to be more sensitive than the previous ones published
in the literature (Table IV).
Consequences for follow-up. The currently recom-
mended follow-up program for aortic stent grafts is
problematic for three major reasons: it involves repeated
irradiation, the contrast agent is nephrotoxic, and the
process is costly.19 Noll et al9 showed that the total cost
of aortic stent graft implantation and follow-up was
$20,000, with a mean cost of follow-up at 5 years of
$11,351 per patient. The extra expenditure was due to
secondary interventions (57%) and radiological examina-
Table V. Anatomic AAA characteristics and stent graft spe
Total po
(n 
Mean external diameter of the AAA (mm)  SD 57
Mean diameter of the subrenal aorta (mm)  SD 25
Mean length of proximal neck (mm)  SD 25
Hypogastric aneurysm
N (%) 17 (
Absence of thrombus
N (%) 74 (
1st-generation stent graft
N (%) 82 (
Degressive stent graft
N (%) 70 (
Aortic extension
N (%) 14 (
SSR, Significant sac reduction.tions (32.5%). Our results suggest that, in patients withSSR at 2 years of follow-up (especially patients treated
with second generation endografts), it may be safe to
reduce the intensity of follow-up. By proposing to switch
to a 2-year interval rather than yearly, the overall addi-
tional cost of 25% of EVAR patients will be halved, and
therefore the mean overall cost of EVAR follow-up at 5
years will be reduced by 10%. A total stop of surveillance
in this sub-group of patients could be proposed; how-
ever, we do think that further studies including more
patients and longer follow-up are needed.
Predictive factors of SSR. It is not surprising that
predictive factors of SSR are anatomic. Correlation be-
tween treatment success and favorable aneurysm anat-
omy has intensively been reported in the literature.
Cambria et al showed that a proximal aortic neck greater
than 26 mm in diameter or shorter than 15 mm in length
was associated with a significantly higher risk of periop-
erative mortality, aneurysm-associated mortality, and
secondary interventions.20,21 In many studies, small an-
eurysms (55mm) were correlated with better out-
comes.22-24 Armon et al proved that small aneurysms are
more suitable for endovascular treatment, as their anat-
omy tends to be more compatible with stent graft im-
plantation.25 As a consequence, current studies are in-
vestigating the benefice of an early EVAR for AAA
smaller than 55 mm.26 Other factors favoring aneurysm
shrinkage are also present in the literature, but were not
found to be significant in our series. Bertges et al27 found
that shrinkage was correlated with the type and the
manufacturer of the stent graft implanted. We noticed
that patients who had a first-generation endograft were
less prone to SSR, but the difference was not significant.
Also, almost all complications that occurred in the SSR
group concerned first-generation endografts, although
the efficient management of these complications autho-
rized a secondary SSR. The presence and the volume of
mural thrombus have also been correlated to less aneu-
rysm shrinkage,23,28 but their possible role and signifi-
cance remain a matter of debate.29 We did not evaluate
ities
tion SSR group
(n  92)
Non-SSR group
(n  279) P
53  5 58  9 .0001
24  3 25  3 .001
27  11 24  10 .05
2 (2.2) 15 (5.4) .20
16 (17.4) 58 (20.8) .46
16 (17.4) 66 (23.7) .20
14 (15.2) 56 (20.1) .30
4 (4.3) 10 (3.6) .11cific
pula
371)
 9
 11
 10
4.6)
19.9)
22.2)
18.9)
3.8)mural thrombi by quantitative measurements of volume
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absence of correlation between mural thrombus and SSR
in our study.
CONCLUSION
SSR, defined as a decrease greater than 75% in the
difference between the largest diameter of the aneurysm
(D) and the diameter of the body of the stent graft (D1),
appears to be a reliable prognostic factor of the long-term
success of endovascular treatment for AAA. If long-term
follow-up studies (10 years) confirm this stability, it would
be legitimate to carry out less intensive monitoring from
the second year of follow-up, with longer intervals between
consultations and imaging. This would significantly de-
crease the costs associated with endovascular treatment.
Anatomic feasibility is correlated with the occurrence of
SSR, and, therefore, with long-term treatment success. It
remains the major parameter to take into account when
choosing the AAA treatment modality.
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